tacrolimus extended release + mycophenolate mofetil

Tacrolimus extended release + mycophenolate mofetil is a combination immunosuppressive regimen mainly used in the prevention of organ transplant rejection, particularly in kidney transplantation. **Tacrolimus extended release** is a calcineurin inhibitor that binds FK506-binding protein, inhibiting calcineurin and consequently blocking the transcription of interleukin-2 (IL-2), a cytokine critical for T-cell activation. **Mycophenolate mofetil** is a prodrug converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase, suppressing de novo purine synthesis required for T- and B-lymphocyte proliferation. Together, these agents provide potent immunosuppression by complementary mechanisms, significantly reducing the risk of acute graft rejection but also requiring careful monitoring due to their toxicity profiles, especially nephrotoxicity (tacrolimus) and myelosuppression/gastrointestinal effects (mycophenolate mofetil)[1][2].

Brand names

Envarsus XRCellCeptAdvagrafAstagraf XL

Other names

tacrolimus ER + mycophenolate mofetiltacrolimus XR + mycophenolate mofetil